(ILCB) Morningstar U.S. Equity - Overview
Etf: Large-Cap, Mid-Cap, Blend, Equity, US
Dividends
| Dividend Yield | 1.22% |
| Yield on Cost 5y | 2.01% |
| Yield CAGR 5y | -4.51% |
| Payout Consistency | 97.1% |
| Payout Ratio | - |
| Risk 5d forecast | |
|---|---|
| Volatility | 15.9% |
| Relative Tail Risk | 5.06% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.61 |
| Alpha | -0.28 |
| Character TTM | |
|---|---|
| Beta | 0.968 |
| Beta Downside | 0.980 |
| Drawdowns 3y | |
|---|---|
| Max DD | 19.05% |
| CAGR/Max DD | 1.11 |
Description: ILCB Morningstar U.S. Equity January 20, 2026
The iShares Morningstar U.S. Equity ETF (ILCB) seeks to track a Morningstar-defined index that blends large-cap growth and value stocks. By law, the fund must allocate at least 80 % of its net assets to the index’s component securities or to securities that are “substantially identical” in economic characteristics, thereby ensuring tight tracking error.
As of the most recent filing (Q4 2023), ILCB carries an expense ratio of 0.20 % and manages roughly $3.2 billion in assets. Its top ten holdings are dominated by mega-caps such as Apple, Microsoft, and Johnson & Johnson, which together account for about 22 % of the portfolio. Sector exposure is roughly 40 % technology, 20 % healthcare, and 15 % consumer discretionary, reflecting the “large-blend” classification.
Key drivers of performance include U.S. monetary policy (the Fed’s stance on interest rates directly impacts growth-oriented tech valuations) and corporate earnings trends in the consumer-discretionary and healthcare sectors, which historically weigh heavily in the Morningstar growth/value blend. A recent shift toward higher inflation expectations could compress valuation multiples for growth stocks, while a resilient labor market supports consumer spending and thus benefits the blend’s value side.
For a deeper, data-rich assessment of how ILCB fits into a diversified portfolio, consider exploring ValueRay’s analytical tools.
What is the price of ILCB shares?
Over the past week, the price has changed by -0.73%, over one month by -0.05%, over three months by +1.31% and over the past year by +14.92%.
Is ILCB a buy, sell or hold?
What are the forecasts/targets for the ILCB price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | - | - |
| Analysts Target Price | - | - |
| ValueRay Target Price | 112.1 | 17.5% |
ILCB Fundamental Data Overview February 04, 2026
EBIT TTM = 0.0 USD
EBITDA TTM = 0.0 USD
Long Term Debt = unknown (none)
Short Term Debt = unknown (none)
Debt = unknown
Net Debt = unknown
Enterprise Value = 1.19b USD (1.19b + (null Debt) - (null CCE))
Interest Coverage Ratio = unknown (Ebit TTM 0.0 / Interest Expense TTM 0.0)
EV/FCF = unknown (FCF TTM 0.0)
FCF Yield = 0.0% (FCF TTM 0.0 / Enterprise Value 1.19b)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 0.0) / Revenue TTM)
Tobins Q-Ratio = unknown (Enterprise Value 1.19b / Total Assets none)
Interest Expense / Debt = unknown (Interest Expense 0.0 / Debt none)
Taxrate = 21.0% (US default 21%)
NOPAT = 0.0 (EBIT 0.0 * (1 - 21.00%))
Current Ratio = unknown (Total Current Assets none / Total Current Liabilities none)
Debt / Equity = unknown (Debt none)
Debt / EBITDA = unknown (Net Debt none / EBITDA 0.0)
Debt / FCF = unknown (Net Debt none / FCF TTM 0.0)
Total Stockholder Equity = 0.0 (from calculated bookValueOfEquity)
RoA = unknown (Net Income 0.0 / Total Assets none)
RoE = unknown (Net Income TTM 0.0 / Total Stockholder Equity 0.0)
RoCE = unknown (EBIT 0.0 / Capital Employed )
RoIC = unknown (NOPAT 0.0, Invested Capital 0.0, EBIT 0.0)
WACC = 9.48% (E(1.19b)/V(1.19b) * Re(9.48%) + (debt-free company))
Discount Rate = 9.48% (= CAPM, Blume Beta Adj.)
Fair Price DCF = unknown (Cash Flow 0.0)